Quantifying multimodal contrast agent biological activity using near-infrared flow cytometry

Contrast Media and Molecular Imaging

Volumn 7, Issue 3, 2012, Pages 338-345

  Hall, Mary A ^a   Aldrich, Melissa B ^a   Azhdarinia, Ali ^a   Lachance, Pier Anne ^a   Robinson, Holly ^a   Hazen, Amy ^a   Haviland, David L ^a   Sevick Muraca, Eva M ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Antibody (Ab); Epithelial cell adhesion molecule (EpCAM); Lindmo method; Monoclonal antibody (mAb); Multimodal contrast agent; Multimodality imaging; Near infrared (NIR); Near infrared flow cytometry (NIR FC)

Indexed keywords

ANTIBODY; CONTRAST MEDIUM; COPPER 64; EPITHELIAL CELL ADHESION MOLECULE; MONOCLONAL ANTIBODY; TETRAXETAN;

ARTICLE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; ISOTOPE LABELING; NEAR INFRARED SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; CONTRAST MEDIA; FLOW CYTOMETRY; FLUORESCENT DYES; HUMANS; INDOLES; MALE; MOLECULAR IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOIMMUNOASSAY; SENSITIVITY AND SPECIFICITY; SPECTROSCOPY, NEAR-INFRARED; SUCCINIMIDES; TUMOR CELLS, CULTURED;

EID: 84860356052     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.502     Document Type: Article

References (30)

1. Olafsen T, Wu AM. Antibody vectors for imaging. Semin Nucl Med 2010; 40(3): 167-181.
2. Yordanov AT, Hens M, Pegram C, Bigner DD, Zalutsky MR. Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands. Nucl Med Biol 2007; 34(2): 173-183.
3. Visser GW, Gerretsen M, Herscheid JD, Snow GB, van Dongen G. Labeling of monoclonal antibodies with rhenium-186 using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol. J Nucl Med 1993; 34(11): 1953-1963.
4. Tahtis K, Lee FT, Smyth FE, Power BE, Renner C, Brechbiel MW, Old LJ, Hudson PJ, Scott AM. Biodistribution properties of (111)indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab')(2) constructs in a breast carcinoma xenograft model. Clin Cancer Res 2001; 7(4): 1061-1072.
5. Smith-Jones PM, Fridrich R, Kaden TA, Novak-Hofer I, Siebold K, Tschudin D, Maecke HR. Antibody labeling with copper-67 using the bifunctional macrocycle 4-[(1, 4, 8, 11-tetraazacyclotetradec-1-yl)methyl]benzoic acid. Bioconjug Chem 1991; 2(6): 415-421.
6. Pimm MV, Paul MA, Ogumuyiwa Y, Baldwin RW. Biodistribution and tumour localisation of a daunomycin-monoclonal antibody conjugate in nude mice with human tumour xenografts. Cancer Immunol Immunother 1988; 27(3): 267-271.
7. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA, Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984; 72(1): 77-89.
8. Lee FT, Hall C, Rigopoulos A, Zweit J, Pathmaraj K, O'Keefe GJ, Smyth FE, Welt S, Old LJ, Scott AM. Immuno-PET of human colon xenograft-bearing BALB/c nude mice using 124I-CDR-grafted humanized A33 monoclonal antibody. J Nucl Med 2001; 42(5): 764-769.
9. Ngai WM, Reilly RM. A simple method to determine the immunoreactivity of radiolabelled monoclonal antibodies to the TAG-72 antigen. Appl Radiat Isot 1993; 44(9): 1193-1197.
10. Mattes MJ. Limitations of the Lindmo method in determining antibody immunoreactivity. Int J Cancer 1995; 61(2): 286-288.
11. Konishi S, Hamacher K, Vallabhajosula S, Kothari P, Bastidas D, Bander N, Goldsmith S. Determination of immunoreactive fraction of radiolabeled monoclonal antibodies: what is an appropriate method? Cancer Biother Radiopharm 2004; 19(6): 706-715.
12. Frandsen TP, Naested H, Rasmussen SK, Hauptig P, Wiberg FC, Rasmussen LK, Jensen AM, Persson P, Wiken M, Engstrom A, Jiang Y, Thorpe SJ, Forberg C, Tolstrup AB. Consistent manufacturing and quality control of a highly complex recombinant polyclonal antibody product for human therapeutic use. Biotechnol Bioeng 2011; 108(9): 2171-2181.
13. Bordeaux J, Welsh A, Agarwal S, Killiam E, Baquero M, Hanna J, Anagnostou V, Rimm D. Antibody validation. Biotechniques 2010; 48(3): 197-209.
14. Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, Kononen J, Simon R, Sauter G, Baeuerle PA. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 2006; 94(1): 128-135.
15. Fong D, Steurer M, Obrist P, Barbieri V, Margreiter R, Amberger A, Laimer K, Gastl G, Tzankov A, Spizzo G. Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance. J Clin Pathol 2008; 61(1): 31-35.
16. Poczatek RB, Myers RB, Manne U, Oelschlager DK, Weiss HL, Bostwick DG, Grizzle WE. Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. J Urol 1999; 162(4): 1462-1466.
17. Spizzo G, Went P, Dirnhofer S, Obrist P, Moch H, Baeuerle PA, Mueller-Holzner E, Marth C, Gastl G, Zeimet AG. Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol 2006; 103(2): 483-488.
18. Spizzo G, Went P, Dirnhofer S, Obrist P, Simon R, Spichtin H, Maurer R, Metzger U, von Castelberg B, Bart R, Stopatschinskaya S, Kochli OR, Haas P, Mross F, Zuber M, Dietrich H, Bischoff S, Mirlacher M, Sauter G, Gastl G. High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat 2004; 86(3): 207-213.
19. Hall MA, Sunkuk K, Robinson H, Lachance P, Azhdarinia A, Ranganathan R, Price R, Chan W, Sevick-Muraca EM. Imaging prostate cancer lymph node metastases with a multimodality contrast agent. Prostate 2012; 72(2): 129-146.
20. Sirk SJ, Olafsen T, Barat B, Bauer KB, Wu AM. Site-specific, thiol-mediated conjugation of fluorescent probes to cysteine-modified diabodies targeting CD20 or HER2. Bioconjug Chem 2008; 19(12): 2527-2534.
21. de Tute RM. Flow cytometry and its use in the diagnosis and management of mature lymphoid malignancies. Histopathology 2011; 58: 90-105.
22. Yuan CM, Stetler-Stevenson M. Role of flow cytometry of peripheral blood and bone marrow aspirates in early myeloma. Semin Hematol 2011; 48(1): 32-38.
23. Varma N, Naseem S. Application of flow cytometry in pediatric hematology-oncology. Pediatr Blood Cancer 2011; 57(1): 18-29.
24. Cedeno-Arias M, Sanchez-Ramirez J, Blanco-Santana R, Rengifo-Calzado E. Validation of a flow cytometry based binding assay for evaluation of monoclonal antibody recognizing EGF receptor. Sci Pharm 2011; 79(3): 569-581.
25. Lisy MR, Goermar A, Thomas C, Pauli J, Resch-Genger U, Kaiser WA, Hilger I. In vivo near-infrared fluorescence imaging of carcinoembryonic antigen-expressing tumor cells in mice. Radiology 2008; 247(3): 779-787.
26. Gleysteen JP, Newman JR, Chhieng D, Frost A, Zinn KR, Rosenthal EL. Fluorescent labeled anti-EGFR antibody for identification of regional and distant metastasis in a preclinical xenograft model. Head Neck 2008; 30(6): 782-789.
27. Sampath L, Kwon S, Ke S, Wang W, Schiff R, Mawad ME, Sevick-Muraca EM. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. J Nucl Med 2007; 48(9): 1501-1510.
28. Sevick-Muraca EM. Translation of near-infrared fluorescence imaging technologies: Emerging clinical applications. Ann Rev Med 2012; 63: 217-231.
29. 3. Cancer Res 2006; 66(19): 9673-9681.
30. Pulukuri SM, Gondi CS, Lakka SS, Jutla A, Estes N, Gujrati M, Rao JS. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 2005; 280(43): 36529-36540.